In Reply
- PMID: 32378772
- PMCID: PMC7267302
- DOI: 10.1634/theoncologist.2020-0329
In Reply
Abstract
This letter to the editor remarks on additional considerations for the management of febrile neutropenia during the COVID‐19 pandemic, in response to the letter by Boutayeb et al.
Comment on
-
How to Manage Febrile Neutropenia During the COVID Pandemic?Oncologist. 2020 Aug;25(8):e1251. doi: 10.1634/theoncologist.2020-0285. Epub 2020 May 27. Oncologist. 2020. PMID: 32399999 Free PMC article.
References
-
- Freifeld AG, Bow EJ, Sepkowitz KA et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–e93. - PubMed
-
- Klastersky J, de Naurois J, Rolston K et al. ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 2016;27(suppl 5):v111–v118. - PubMed